IP Library Granted Patent US 9,938,354
Granted Patent B2
US 9,938,354 · App. 14/269,041 · Granted Apr 10, 2018

Lin28-mediated control of let-7 biogenesis

Inventors: Richard I. Gregory (Brookline, MA); Elena Piskounova (Dallas, TX); Dimitrios Iliopoulos (Los Angeles, CA)
Assignees: Dana-Farber Cancer Institute, Inc.; Children's Medical Center Corporation
C07K16/40A61K31/713A61K31/7105C07K2/00C12N15/111C12N15/115C12N15/1137C12N2310/14C12N2310/141C12N2320/10C12N2320/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,938,354
App. No.
14/269,041
Granted
Apr 10, 2018
Kind
B2
Abstract

The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogenesis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3′ terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.

Claims (12)

1. A method of high throughput screening of agents that derepress let-7 expression, the method comprising:

providing a recombinant functional domain of mammalian terminal uridyly transferase (TUTase) ZCCHC11 or ZCCHC6, a recombinant functional domain of mammalian Lin28A, and a let-7 miRNA precursor in an assay;

adding an agent to said assay;

monitoring 3′ TUTase activity; and

identifying the agent as an agent that derepresses let-7 expression if it inhibits TUTase activity as compared to an agent that does not derepress let-7 expression.

2. The method of claim 1 , wherein the assay is an in vitro assay.

3. The method of claim 1 , wherein the assay is a cell-based assay.

4. The method of claim 1 , wherein the agent is a compound from a compound library.

5. The method of claim 4 , wherein the compound library is a chemical library, a bioactive compound library, or a natural product extract library.

6. The method of claim 1 , wherein the TUTase is ZCCHC 11.

7. The method of claim 1 , wherein the TUTase is ZCCHC 6.

8. The method of claim 1 , wherein the functional domain of mammalian TUTase comprises a N-terminal C2H2 zinc finger.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 16, 2024
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066338/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: ILIOPOULOS, DIMITRIOS
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 036305/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: GREGORY, RICHARD I.; PISKOUNOVA, ELENA
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 036305/0581 →
Continuity (4)
Continuation 14007465
Provisional Application 61562706 · Nov 22, 2011
Provisional Application 61467427 · Mar 25, 2011
Related Publication 20140328858A1 · Nov 6, 2014